SMTL ID : 6i3u.1

Optimization of potent and selective ATM inhibitors suitable for a proof-of-concept study in Huntington's disease models

Coordinates

PDB Format

Method

X-RAY DIFFRACTION 2.09 Å

Oligo State

monomer

Ligands

1 x H2E: 2-morpholin-4-yl-6-[7-[(2~{R})-1-morpholin-4-ylpropan-2-yl]oxy-9~{H}-thioxanthen-4-yl]pyran-4-one(Non-covalent)

H2E.1: 16 residues within 4Å: Chain A: A.347, K.348, S.349, L.369, K.371, Y.405, L.417, Q.418, W.419, I.420, S.423, P.425, L.486, F.494, I.496, D.497 14 PLIP interactions: 14 interactions with chain A Hydrophobic interactions: A:A.347, A:L.369, A:L.417, A:W.419, A:W.419, A:L.486, A:I.496, A:I.496 Hydrogen bonds: A:K.371, A:I.420, A:S.423, A:D.497 Water bridges: A:Q.355, A:Q.421

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Toledo-Sherman, L. et al., Optimization of Potent and Selective Ataxia Telangiectasia-Mutated Inhibitors Suitable for a Proof-of-Concept Study in Huntington's Disease Models. J.Med.Chem. (2019)

Release Date

2019-03-20

Peptides

Phosphatidylinositol 3-kinase catalytic subunit type 3: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

Phosphatidylinositol 3-kinase catalytic subunit type 3